Estrogen Shortage Impacts Menopause Treatment Access Across the U.S.

A nationwide shortage of estrogen, a key medication for managing menopause symptoms, is creating difficulties for patients and pharmacies across the country. The shortage, particularly affecting transdermal estrogen patches, comes after the U.S. Food and Drug Administration (FDA) removed a long-standing “black box” warning regarding hormone therapy in 2025.

Why the Sudden Shortage?

The removal of the black box warning, which previously cautioned about potential risks of breast cancer, dementia, and cardiovascular disease associated with hormone therapy, has led to increased demand for estrogen products. U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. Stated the previous warnings were based on “poor science and bureaucratic inertia.” The increased demand, coupled with manufacturing complexities specific to transdermal patches, is contributing to the current supply issues.

Emily Zadvorny, CEO of the Colorado Pharmacists Society, explained in an email that “the shortage is at least partially attributed to greatly increased demand. It is also formulation specific, with the patches being most in shortage, given that they are more complex to manufacture.” She also noted that other formulations of FDA-approved estrogen products remain available, and some patients are opting for compounded formulations, though these are often more expensive and may not be fully covered by insurance.

Impact on Patients and Pharmacies

Pharmacies across the country are struggling to maintain adequate stock levels. Capitol Heights Pharmacy in Denver, Colorado, has experienced difficulties keeping the medication in stock, while Front Range Pharmacy in Englewood, Colorado, waited over a month for an estrogen shipment from a distributor in Commerce City.

CVS Pharmacy acknowledged the issue in a statement, noting that there hasn’t been a “sufficient supply” of hormone replacement therapies in recent weeks. Amy Thibault, executive director of corporate communications for CVS, indicated that manufacturers are best positioned to explain challenges within their ingredient supply chain.

However, some larger healthcare institutions, like Denver Health, report being less affected. A spokesperson for Denver Health stated that their OB-GYN and pharmacy teams have not experienced issues filling prescriptions for vaginal estrogen and estrogen patches.

Patient Concerns

The shortage is causing frustration for patients relying on estrogen therapy to manage menopause symptoms. One individual expressed concern about the impact on the workforce, stating, “Menopausal women are an active part of the workforce, and without these supplements, quality of sleep is impacted which has far-reaching implications. As of this weekend, pharmacies are unable to confirm when they will be able to refill prescriptions.”

Looking Ahead

The situation remains fluid, and the duration of the shortage is uncertain. Pharmacists and healthcare providers are working to locate alternative solutions for patients, including exploring different formulations of estrogen and considering compounded medications when appropriate. Continued monitoring of the supply chain and communication between manufacturers, pharmacies, and healthcare providers will be crucial to mitigating the impact of this shortage.